Itamar Raz

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7280818/publications.pdf

Version: 2024-02-01

165 papers	19,123 citations	41258 49 h-index	11899 134 g-index
171 all docs	171 docs citations	171 times ranked	15504 citing authors

#	Article	IF	Citations
1	Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin. European Journal of Preventive Cardiology, 2022, 29, 1352-1360.	0.8	26
2	Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLAREâ€“TIMI 58 trial. European Heart Journal, 2022, 43, 2958-2967.	1.0	28
3	Myopia and Early-Onset Type 2 Diabetes: A Nationwide Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e663-e671.	1.8	3
4	Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58. Diabetes Care, 2022, 45, 938-946.	4.3	20
5	Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58. Diabetes Care, 2022, 45, e27-e29.	4.3	10
6	Letter Regarding Normal Albuminuria in Patients With Autopsy-Proven Advanced Diabetic Nephropathy. Kidney International Reports, 2022, 7, 662.	0.4	1
7	Cytochrome c Oxidase Activity as a Metabolic Regulator in Pancreatic Beta-Cells. Cells, 2022, 11, 929.	1.8	7
8	Comment on Oosterwijk et al. High-Normal Protein Intake Is Not Associated With Faster Renal Function Deterioration in Patients With Type 2 Diabetes: A Prospective Analysis in the DIALECT Cohort. Diabetes Care 2022;45:35â€“41. Diabetes Care, 2022, 45, e67-e68.	4.3	2
9	Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. Circulation, 2022, 145, 1460-1470.	1.6	97
10	Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. Circulation, 2022, 145, 1581-1591.	1.6	13
11	<scp>MMC</scp> celebrating 6â€‰years of experience and expansion. Journal of Diabetes, 2022, , .	0.8	1
12	Obesity in late adolescence and incident type 1 diabetes in young adulthood. Diabetologia, 2022, 65, 1473-1482.	2.9	18
13	Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodiumâ€“glucose coâ€transporter 2 inhibitor therapy in <scp>DECLAREâ€TIMI</scp> 58. European Journal of Heart Failure, 2021, 23, 1026-1036.	2.9	35
14	Haemoglobin A1c is a predictor of COVIDâ€19 severity in patients with diabetes. Diabetes/Metabolism Research and Reviews, 2021, 37, e3398.	1.7	61
15	Adolescent Hypertension and Risk for Early-Onset Type 2 Diabetes: A Nationwide Study of 1.9 Million Israeli Adolescents. Diabetes Care, 2021, 44, e6-e8.	4.3	8
16	<scp>NAFLD</scp>in type 2 diabetes mellitus: Still many challenging questions. Diabetes/Metabolism Research and Reviews, 2021, 37, e3386.	1.7	18
17	Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation, 2021, 143, 470-478.	1.6	32
18	Management of patients with diabetes and obesity in the COVID-19 era: Experiences and learnings from South and East Europe, the Middle East, and Africa. Diabetes Research and Clinical Practice, 2021, 172, 108617.	1.1	31

#	Article	IF	Citations
19	Adolescent Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Young Adulthood. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e34-e44.	1.8	13
20	Tackling obesity during the COVIDâ€19 pandemic. Diabetes/Metabolism Research and Reviews, 2021, 37, e3393.	1.7	2
21	Cardiorenal outcomes with dapagliflozin by baseline glucoseâ€lowering agents: Post hoc analyses from <scp>DECLAREâ€TIMI</scp> 58. Diabetes, Obesity and Metabolism, 2021, 23, 29-38.	2.2	28
22	Stuttering and Incident Type 2 Diabetes: A Population-Based Study of 2.2 Million Adolescents. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e978-e987.	1.8	4
23	Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial. Diabetes Care, 2021, 44, 1020-1026.	4.3	30
24	The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus. Diabetologia, 2021, 64, 1226-1234.	2.9	15
25	Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. Circulation Genomic and Precision Medicine, 2021, 14, e003006.	1.6	6
26	Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. Diabetes Care, 2021, 44, 1159-1167.	4.3	25
27	From glucose lowering agents to disease/diabetes modifying drugs: a â€œSIMPLEâ€•approach for the treatment of type 2 diabetes. Cardiovascular Diabetology, 2021, 20, 92.	2.7	28
28	Preinfection glycaemic control and disease severity among patients with type <scp>2</scp> diabetes and <scp>COVIDâ€19</scp>: A retrospective, cohort study. Diabetes, Obesity and Metabolism, 2021, 23, 1995-2000.	2.2	9
29	Adolescent Thyroid Disorders and Risk for Type 2 Diabetes in Young Adulthood. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3426-e3435.	1.8	8
30	Effect of a primary-care-team focused diabetes educational program project on diabetes care quality indicators in a large health maintenance organization. Diabetes Research and Clinical Practice, 2021, 177, 108896.	1.1	4
31	Asthma in Youth and Early-onset Type 2 Diabetes: A Nationwide Study of 1.72 Million Israeli Adolescents. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e5043-e5053.	1.8	2
32	The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. Diabetes Care, 2021, 44, 1805-1815.	4.3	49
33	Machine learning based study of longitudinal HbA1c trends and their association with allâ€cause mortality: Analyses from a National Diabetes Registry. Diabetes/Metabolism Research and Reviews, 2021, , e3485.	1.7	5
34	Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes. JAMA Cardiology, 2021, 6, 801.	3.0	26
35	Serum from type 2 diabetes patients consuming a three-meal diet resets circadian rhythms in cultured hepatocytes. Diabetes Research and Clinical Practice, 2021, 178, 108941.	1.1	1
36	A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. Diabetes Care, 2021, 44, 2573-2581.	4.3	13

#	Article	IF	Citations
37	Management of diabetic neuropathy. Metabolism: Clinical and Experimental, 2021, 123, 154867.	1.5	20
38	Adolescent cognitive function and incident early-onset type 2 diabetes. EClinicalMedicine, 2021, 41, 101138.	3.2	4
39	Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial). PLoS ONE, 2021, 16, e0259372.	1.1	6
40	Childhood Pancreatitis and Risk for Incident Diabetes in Adulthood. Diabetes Care, 2020, 43, 145-151.	4.3	23
41	SGLT2 inhibitors for primary prevention of cardiovascular events. Journal of Diabetes, 2020, 12, 5-7.	0.8	4
42	Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLAREâ€“TIMI 58 Study. Diabetes Care, 2020, 43, 468-475.	4.3	72
43	Insulin Therapy: Future Perspectives. American Journal of Therapeutics, 2020, 27, e121-e132.	0.5	28
44	Five years into the Israeli National Diabetes Program â€“ are we on the right track?. Diabetes/Metabolism Research and Reviews, 2020, 37, e3421.	1.7	1
45	Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. Circulation, 2020, 142, 734-747.	1.6	44
46	Response by Zelniker et al to Letter Regarding Article, â€œEffect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trialâ€. Circulation, 2020, 142, e129-e130.	1.6	6
47	Adolescent BMI and early-onset type 2 diabetes among Ethiopian immigrants and their descendants: a nationwide study. Cardiovascular Diabetology, 2020, 19, 168.	2.7	9
48	The relationship between inpatient hyperglycaemia and mortality is modified by baseline glycaemic status. Diabetes/Metabolism Research and Reviews, 2020, 37, e3420.	1.7	4
49	Positioning sulphonylureas in a modern treatment algorithm for patients with type 2 diabetes: Expert opinion from a European consensus panel. Diabetes, Obesity and Metabolism, 2020, 22, 1705-1713.	2.2	17
50	Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the <scp>LEADER</scp> randomized trial. Diabetes, Obesity and Metabolism, 2020, 22, 2077-2088.	2.2	10
51	Digital Diabetes Care System Observations from a Pilot Evaluation Study in Vietnam. International Journal of Environmental Research and Public Health, 2020, 17, 937.	1.2	5
52	Cardiovascular and renal benefits of dapagliflozin in patients with short and longâ€standing type 2 diabetes: Analysis from the DECLAREâ€TIMI 58 trial. Diabetes, Obesity and Metabolism, 2020, 22, 1122-1131.	2.2	16
53	Prediction of progression from preâ€diabetes to diabetes: Development and validation of a machine learning model. Diabetes/Metabolism Research and Reviews, 2020, 36, e3252.	1.7	50
54	Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus. Circulation, 2020, 141, 1227-1234.	1.6	241

#	Article	IF	Citations
55	Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLAREâ€TIMI 58 study. Diabetes, Obesity and Metabolism, 2020, 22, 1357-1368.	2.2	26
56	Adolescent Obesity and Early-Onset Type 2 Diabetes. Diabetes Care, 2020, 43, 1487-1495.	4.3	84
57	Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 465-473.	2.2	32
58	Abstract 16139: A Targeted Proteomic Approach to Identify Circulating Biomarkers of Heart Failure Risk in Patients With Type 2 Diabetes Mellitus in DECLARE-TIMI 58. Circulation, 2020, 142, .	1.6	1
59	Abstract 13702: A Novel Genetic Risk Score Predicts Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation, 2020, 142, .	1.6	0
60	Abstract 15701: Relationship Between Cardiac Biomarkers and Major Adverse Cardiovascular Events in DECLARE-TIMI 58. Circulation, 2020, 142, .	1.6	1
61	Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction. Circulation, 2019, 140, 1004-1014.	1.6	70
62	Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Circulation, 2019, 140, 1569-1577.	1.6	94
63	SGLT-2 inhibitors for people with type 2 diabetes â€“ Authors' reply. Lancet, The, 2019, 394, 560-561.	6.3	6
64	Reduction in Glycated Hemoglobin and Daily Insulin Dose Alongside Circadian Clock Upregulation in Patients With Type 2 Diabetes Consuming a Three-Meal Diet: A Randomized Clinical Trial. Diabetes Care, 2019, 42, 2171-2180.	4.3	54
65	Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLAREâ€“TIMI 58 randomised trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 606-617.	5.5	482
66	Response by Mann et al to Letter Regarding Article, â€œEffects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trialâ€• Circulation, 2019, 139, e1017-e1018.	1.6	1
67	Effect of Injection Site Cooling and Warming on Insulin Glargine Pharmacokinetics and Pharmacodynamics. Journal of Diabetes Science and Technology, 2019, 13, 1123-1128.	1.3	2
68	Effect of Flash Glucose Monitoring Technology on Glycemic Control and Treatment Satisfaction in Patients With Type 2 Diabetes. Diabetes Care, 2019, 42, 1178-1184.	4.3	120
69	Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus: Observations from SAVOR-TIMI 53. Clinical Chemistry, 2019, 65, 781-790.	1.5	8
70	Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation, 2019, 139, 2516-2527.	1.6	224
71	Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation, 2019, 139, 2528-2536.	1.6	415
72	An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes. Expert Opinion on Pharmacotherapy, 2019, 20, 781-790.	0.9	4

#	Article	IF	Citations
73	Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation, 2019, 139, 2022-2031.	1.6	523
74	The SONAR studyâ€"is there a future for endothelin receptor antagonists in diabetic kidney disease?. Annals of Translational Medicine, 2019, 7, S330-S330.	0.7	5
75	Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2019, 380, 347-357.	13.9	4,159
76	SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet, The, 2019, 393, 31-39.	6.3	1,958
77	Validity of diagnostic codes and estimation of prevalence of diabetic foot ulcers using a large electronic medical record database. Diabetes/Metabolism Research and Reviews, 2019, 35, e3094.	1.7	7
78	Incidence and Risk Factors for Mortality Following Bariatric Surgery: a Nationwide Registry Study. Obesity Surgery, 2018, 28, 2661-2669.	1.1	25
79	The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)â€"TIMI 58 Trial. American Heart Journal, 2018, 200, 83-89.	1.2	117
80	Calculating individualized glycaemic targets using an algorithm based on expert worldwide diabetologists: Implications in realâ€life clinical practice. Diabetes/Metabolism Research and Reviews, 2018, 34, e2976.	1.7	7
81	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditorsâ€™ Expert Forum. Diabetes Care, 2018, 41, 14-31.	4.3	338
82	<scp>DECLAREâ€TIMI</scp> 58: Participantsâ€™ baseline characteristics. Diabetes, Obesity and Metabolism, 2018, 20, 1102-1110.	2.2	96
83	The Berlin Declaration: A call to action to improve early actions related to type 2 diabetes. How can specialist care help?. Diabetes Research and Clinical Practice, 2018, 139, 392-399.	1.1	13
84	Digital health technology and diabetes management. Journal of Diabetes, 2018, 10, 10-17.	0.8	74
85	Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease. Diabetes Care, 2018, 41, 577-585.	4.3	25
86	Patient clusters based on HbA1c trajectories: A step toward individualized medicine in type 2 diabetes. PLoS ONE, 2018, 13, e0207096.	1.1	32
87	Comparison Of Hba1C Goals Proposed By An Algorithm To Those Set By Different Members Of Healthcare Teams Within The Dartmouth Hitchcock Health System. Endocrine Practice, 2018, 24, 705-709.	1.1	2
88	Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease. Circulation, 2018, 138, 2908-2918.	1.6	88
89	Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease. Cardiovascular Diabetology, 2018, 17, 117.	2.7	8
90	Glycemic Targets and Prevention of Chronic Complications. Endocrinology, 2018, , 1-31.	0.1	0

#	Article	IF	Citations
91	The Berlin Declaration: A call to improve early actions related to type 2 diabetes. Why is primary care important?. Primary Care Diabetes, 2018, 12, 383-392.	0.9	10
92	Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk. JAMA Cardiology, 2018, 3, 155.	3.0	78
93	Glycemic Targets and Prevention of Chronic Complications. Endocrinology, 2018, , 421-450.	0.1	0
94	The role of insulin pump therapy for type 2 diabetes mellitus. Diabetes/Metabolism Research and Reviews, 2017, 33, e2822.	1.7	24
95	Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes. Expert Review of Clinical Pharmacology, 2017, 10, 535-547.	1.3	17
96	Hypoglycaemia manifestations and recurrent events: <scp>L</scp>essons from the <scp>SAVORâ€TIMI</scp> 53 outcome study. Diabetes, Obesity and Metabolism, 2017, 19, 1045-1050.	2.2	5
97	Response to Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editorsâ€™ Expert Forum. Diabetes Care 2016;39:1186â€“1201. Diabetes Care, 2017, 40, e23-e24.	4.3	1
98	Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial. Diabetes Research and Clinical Practice, 2017, 130, 24-33.	1.1	22
99	Influences of Breakfast on Clock Gene Expression and Postprandial Glycemia in Healthy Individuals and Individuals With Diabetes: A Randomized Clinical Trial. Diabetes Care, 2017, 40, 1573-1579.	4.3	119
100	Continuous subcutaneous insulin infusionâ€”an opportunity for better care but not a â€œmagic pillâ€• Endocrine, 2017, 56, 4-6.	1.1	1
101	Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial. Diabetes Care, 2017, 40, 69-76.	4.3	205
102	Combined Analysis of Three Large Interventional Trials With Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients With Type 2 Diabetes. Diabetes Care, 2017, 40, 284-286.	4.3	95
103	Comment on Shahraz et al. Do Patient Characteristics Impact Decisions by Clinicians on Hemoglobin A1c Targets? Diabetes Care 2016;38:e145â€“e146. Diabetes Care, 2016, 39, e227-e227.	4.3	1
104	Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial. Diabetes Care, 2016, 39, 1329-1337.	4.3	12
105	Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes. Reviews in Endocrine and Metabolic Disorders, 2016, 17, 117-127.	2.6	5
106	Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk. JAMA Cardiology, 2016, 1, 989.	3.0	77
107	Improved Insulin Pharmacokinetics Using a Novel Microneedle Device for Intradermal Delivery in Patients with Type 2 Diabetes. Diabetes Technology and Therapeutics, 2016, 18, 525-531.	2.4	50
108	Proposing a new design for selfâ€monitoring blood glucose logs. Diabetes/Metabolism Research and Reviews, 2016, 32, 60-62.	1.7	0

#	Article	IF	Citations
109	Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editorsâ€™ Expert Forum. Diabetes Care, 2016, 39, 1186-1201.	4.3	113
110	Treatment of Type 2 Diabetes: From â€œGuidelinesâ€•to â€œPosition Statementsâ€•and Back. Diabetes Care, 2016, 39, S146-S153.	4.3	22
111	Introduction to the 5th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy). Diabetes Care, 2016, 39, S113-S114.	4.3	4
112	Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS. Diabetes Care, 2016, 39, S210-S218.	4.3	18
113	An update on DPP-4 inhibitors in the management of type 2 diabetes. Expert Opinion on Emerging Drugs, 2016, 21, 409-419.	1.0	52
114	SGLT2 inhibitors and heart failure â€” clinical implications. Nature Reviews Cardiology, 2016, 13, 185-186.	6.1	16
115	Saxagliptin for the treatment of diabetes - a focus on safety. Expert Opinion on Drug Safety, 2016, 15, 697-707.	1.0	7
116	Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c. American Journal of Medicine, 2016, 129, 340.e1-340.e8.	0.6	34
117	Upregulation of Mitochondrial Content in Cytochrome c Oxidase Deficient Fibroblasts. PLoS ONE, 2016, 11, e0165417.	1.1	29
118	Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial. Diabetes Care, 2015, 38, 696-705.	4.3	141
119	Type 2 diabetes mellitus. Nature Reviews Disease Primers, 2015, 1, 15019.	18.1	1,308
120	Antidiabetic Effect of Interleukin-1Î² Antibody Therapy Through Î²-Cell Protection in the Cohen Diabetes-Sensitive Rat. Diabetes, 2015, 64, 1780-1785.	0.3	13
121	Evaluation of Long-Term Treatment Effect in a Type 1 Diabetes Intervention Trial: Differences After Stimulation With Glucagon or a Mixed Meal. Diabetes Care 2014;37:1384â€“1391. DOI: 10.2337/dc13-1392. Diabetes Care, 2015, 38, 179-179.	4.3	0
122	The addition of E (Empowerment and Economics) to the ABCD algorithm in diabetes care. Journal of Diabetes and Its Complications, 2015, 29, 599-606.	1.2	17
123	Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial. Diabetes Care, 2015, 38, 1145-1153.	4.3	73
124	Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial. Diabetes Care, 2015, 38, 2142-2150.	4.3	54
125	Clinical Assessment of Individualized Glycemic Goals in Patients With Type 2 Diabetes: Formulation of an Algorithm Based on a Survey Among Leading Worldwide Diabetologists. Diabetes Care, 2015, 38, 2293-2300.	4.3	42
126	Response to Letter Regarding Article, â€œHeart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trialâ€• Circulation, 2015, 132, e121-2.	1.6	61

#	Article	IF	Citations
127	Improved Postprandial Glucose Control Using the InsuPad Device in Insulin-Treated Type 2 Diabetes. Journal of Diabetes Science and Technology, 2015, 9, 639-643.	1.3	4
128	Response to Comment on Home et al. Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges? Diabetes Care 2014;37:1499â€“1508. Diabetes Care, 2014, 37, e247-e247.	4.3	1
129	Incidence of Pancreatitis and Pancreatic Cancer in a Randomized Controlled Multicenter Trial (SAVOR-TIMI 53) of the Dipeptidyl Peptidase-4 Inhibitor Saxagliptin. Diabetes Care, 2014, 37, 2435-2441.	4.3	61
130	Improved pharmacokinetic and pharmacodynamic profiles of insulin analogues using InsuPatch, a local heating device. Diabetes/Metabolism Research and Reviews, 2014, 30, 686-692.	1.7	9
131	Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management. Diabetes Care, 2014, 37, 2647-2659.	4.3	58
132	Treatment of Recent-Onset Type 1 Diabetic Patients With DiaPep277: Results of a Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial. Diabetes Care, 2014, 37, 1392-1400.	4.3	52
133	Evaluation of Long-Term Treatment Effect in a Type 1 Diabetes Intervention Trial: Differences After Stimulation With Glucagon or a Mixed Meal. Diabetes Care, 2014, 37, 1384-1391.	4.3	15
134	Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial. Circulation, 2014, 130, 1579-1588.	1.6	594
135	Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges?. Diabetes Care, 2014, 37, 1499-1508.	4.3	122
136	Guideline Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes. Diabetes Care, 2013, 36, S139-S144.	4.3	57
137	Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. New England Journal of Medicine, 2013, 369, 1317-1326.	13.9	3,017
138	Personalized Management of Hyperglycemia in Type 2 Diabetes: Reflections from a Diabetes Care Editors' Expert Forum. Diabetes Care, 2013, 36, 1779-1788.	4.3	130
139	Emerging gliptins for type 2 diabetes. Expert Opinion on Emerging Drugs, 2013, 18, 245-258.	1.0	30
140	Dietary copper supplementation restores Î²-cell function of Cohen diabetic rats: a link between mitochondrial function and glucose-stimulated insulin secretion. American Journal of Physiology - Endocrinology and Metabolism, 2013, 304, E1023-E1034.	1.8	23
141	Early Insulinization to Prevent Diabetes Progression. Diabetes Care, 2013, 36, S190-S197.	4.3	24
142	Efficacy and Safety of Taspoglutide Monotherapy in Drug-Naive Type 2 Diabetic Patients After 24 Weeks of Treatment. Diabetes Care, 2012, 35, 485-487.	4.3	33
143	Rational therapy for diabetes: early recognition of adverse effects and avoidance of disruptive false alarms. Diabetes/Metabolism Research and Reviews, 2012, 28, 321-324.	1.7	12
144	Post Hoc Subgroup Analysis of the HEART2D Trial Demonstrates Lower Cardiovascular Risk in Older Patients Targeting Postprandial Versus Fasting/Premeal Glycemia. Diabetes Care, 2011, 34, 1511-1513.	4.3	72

#	Article	IF	Citations
145	The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitusâ€"Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 Study. American Heart Journal, 2011, 162, 818-825.e6.	1.2	98
146	Impact of the U.S. Food and Drug Administration Cardiovascular Assessment Requirements on the Development of Novel Antidiabetes Drugs. Diabetes Care, 2011, 34, S101-S106.	4.3	69
147	The Continuing Need for Drug Development and Clinical Trials in Type 2 Diabetes and its Complications: Introduction to The RDS Special Issue. Review of Diabetic Studies, 2011, 8, 288-292.	0.5	1
148	The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach. Diabetes/Metabolism Research and Reviews, 2010, 26, 239-244.	1.7	104
149	Introduction to the Second World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy): Dilemmas in clinical practice. Diabetes Care, 2009, 32, S149-S150.	4.3	2
150	Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. Clinical Therapeutics, 2009, 31, 980-987.	1.1	51
151	Challenges in developing endpoints for type 1 diabetes intervention studies. Diabetes/Metabolism Research and Reviews, 2009, 25, 694-704.	1.7	19
152	Managing labor and delivery of the diabetic mother. Expert Review of Obstetrics and Gynecology, 2009, 4, 547-554.	0.4	3
153	Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial. Diabetes Care, 2009, 32, 381-386.	4.3	320
154	Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Current Medical Research and Opinion, 2008, 24, 537-550.	0.9	228
155	DiaPep277(R) Preserves Endogenous Insulin Production by Immunomodulation in Type 1 Diabetes. Annals of the New York Academy of Sciences, 2006, 1079, 340-344.	1.8	22
156	Immune modulation for prevention of type 1 diabetes mellitus. Trends in Biotechnology, 2005, 23, 128-134.	4.9	42
157	Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage. Diabetes/Metabolism Research and Reviews, 2005, 21, 3-14.	1.7	160
158	Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: An 18-week, randomized, open-label study. Clinical Therapeutics, 2005, 27, 1432-1443.	1.1	31
159	Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy. Clinical Therapeutics, 2003, 25, 3109-3123.	1.1	22
160	Î²-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet, The, 2001, 358, 1749-1753.	6.3	501
161	Rapid activation of glycogen synthase and protein phosphatase in human skeletal muscle after isometric contraction requires an intact circulation. Pflugers Archiv European Journal of Physiology, 1995, 431, 259-265.	1.3	14
162	Effects of human diabetic serum on the in vitro development of early somite rat embryos. Teratology, 1989, 39, 85-92.	1.8	23

#	Article	IF	Citations
163	Pharmacokinetic analysis of sustained-release dosage forms of theophylline in humans: Comparison of single and multiple dose studies. Biopharmaceutics and Drug Disposition, 1987, 8, 427-435.	1.1	7
164	Pharmacokinetics of valproic acid in volunteers after a single dose study. Biopharmaceutics and Drug Disposition, 1985, 6, 33-42.	1.1	16
165	Insulin Therapy and Hypoglycemia - Present and Future. , 0, , .		0